Clinical Trials Browser

Phase 1/2 × cabozantinib × 1 year × Clear all

NCT06811116 2026-03-18

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07293351 2026-03-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT06716853 2026-02-09

TEM-GU

Phase 1/2 Terminated

Carcinoma, Renal Cell

NCT06835972 2026-01-15

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

657 enrolled 57 charts 3 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT05039281 2025-12-19

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Phase 1/2 Recruiting

Glioblastoma, Gliosarcoma

NCT05663710 2025-10-06

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Phase 1/2 Recruiting

Carcinoma, Renal Cell